Brian Park, PharmD, Author at Psychiatry Advisor

ADHD

Viloxazine NDA Submitted for Review as Potential New ADHD Treatment

By

December 3, 2019

The New Drug Application for viloxazine hydrochloride, a serotonin norepinephrine modulating agent, has been submitted to the FDA for the treatment of pediatric patients with ADHD.

PTSD trauma and stressor-related

Potential First-in-Class Therapy Gets Fast-Tracked for PTSD

By

Brian Park, PharmD

November 25, 2019

The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 (Bionomics Limited) for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders.

Schizophrenia and Psychoses

FDA Approves First Transdermal Patch for Treatment of Schizophrenia

By

Brian Park, PharmD

October 23, 2019

The FDA has approved Secuado (asenapine; Noven) transdermal system for the treatment of adults with schizophrenia.

General Psychiatry

FDA Panel Votes on OTC Nicotine Mouth Spray for Smoking Cessation

By

Brian Park, PharmD

September 25, 2019

Nicotine mouth spray is currently approved as a smoking cessation aid in many countries outside the US.

Sleep-Wake Disorders

FDA Approves Wakix For Excessive Daytime Sleepiness In Adults With Narcolepsy

By

Brian Park, PharmD

August 20, 2019

The Food and Drug Administration (FDA) approved Wakix (pitolisant; Harmony Biosciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.

General Psychiatry

FDA Warns of “Cure-All” Products That Actually Contain Bleach

By

Brian Park, PharmD

August 20, 2019

The FDA is warning consumers to stop using products known as Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, and Water Purification Solution due to numerous reports of significant health issues.

Brian Park, PharmD

All articles by Brian Park, PharmD

Viloxazine NDA Submitted for Review as Potential New ADHD Treatment

FDA Approves First Transdermal Patch for Treatment of Schizophrenia

FDA Panel Votes on OTC Nicotine Mouth Spray for Smoking Cessation

FDA Approves Wakix For Excessive Daytime Sleepiness In Adults With Narcolepsy

FDA Warns of “Cure-All” Products That Actually Contain Bleach

Recent Stressful Life Events Linked to Later Verbal Memory Decline